这一公告还表示，辉瑞还非法地宣传了抗精神病药齐拉西酮（Geodon），抗生素利奈唑酮（Zyvox）以及抗癫痫药物普瑞巴林（Lyrica）。
The settlement announcement said Pfizer also illegally promoted the anti-psychotic drug Geodon, the antibiotic Zyvox and the anti-epilepsy drug Lyrica.
结果齐拉西酮组总有效率为64.29%，明显高于利培酮组的42.85%。
Results The overall efficacy rate of ziprasidone (64.29%) was higher than that of risperidone (42.85%).
结果：齐拉西酮有效率为86.7％，无明显增加体重，有直立性低血压、头晕、嗜睡等不良反应。
Results: ziprasidone efficient, without obvious for 86.7% weight, orthostatic hypotension, dizziness, sleepiness and so on adverse reactions.
目的：研究单剂量肌肉注射甲磺酸齐拉西酮后药动学。
OBJECTIVE: To study the pharmacokinetics of a single dose of intramuscularly injected ziprasidone mesylate in healthy volunteers.
而且，自从第二代抗精神病药盐酸齐拉西酮获得美国食品药品监督局批准后，该药也被包括在内。
After its approval by the US Food and Drug Administration, the second-generation antipsychotic, ziprasidone hydrochloride, was also included.
建立了毛细管气相色谱法测定甲磺酸齐拉西酮中残留溶剂乙醇、异丙醇、二氯甲烷、正己烷、四氢呋喃、D MF、丙二酸二甲酯的残留量。
A capillary GC method with FID detector for the determination of residual organic solvents ethanol, isopropanol, dichloromethane, n-hexane, tetrahydrofuran, DMF and dimethyl malonate was established.
目的：观察女性精神病患者选用齐拉西酮片和利培酮片治疗前后催乳素水平的变化、溢乳及闭经情况，为临床用药提供参考。
Objective:To observe the prolactin level, amenorrhea and galactorrhea by Ziprasidone verse Risperidone in treatment of female schizophrenias providing reference for clinical use.
对41例(73 %)的，他当时的反应齐拉西酮或氯丙嗪，有30人能在这方面的反应就齐拉西酮。
Of the 41 patients (73 percent) who responded to ziprasidone or chlorpromazine, 30 were able to maintain this response on ziprasidone.
采用阳性症状量表和阴性症状量表(PANSS)以评定齐拉西酮对女性精神分裂症的疗效，采用不良反应量表(TESS)评定该药物的副反应。
The positive and negative symptom scale (PANSS) is adopted to appraise the curative effect, and the treatment emergent symptom scale (TESS) is adopted to appraise by-reaction.
治疗6、8周末TESS评分，齐拉西酮组均低于利培酮组，两组有显著性差异（P<0.01）。
The scores of TESS of study group were significantly lower than those of control group at 6, 8 weekend (P<0.01).
齐拉西酮组总不良反应发生率为42.4%，阿立哌唑组总不良反应发生率为57.6%。
The incidence rate of adverse effect is 42.4% in Ziprasidone group and that is 57.6% in Aripiprazole group.
齐拉西酮组总不良反应发生率为42.4%，阿立哌唑组总不良反应发生率为57.6%。
The incidence rate of adverse effect is 42.4% in Ziprasidone group and that is 57.6% in Aripiprazole group.
应用推荐